Observational Study of Diffuse Intrinsic Pontine Glioma and Brainstem Glioma
This study is collecting samples from children and young adults (up to 21 years old) with diffuse intrinsic pontine glioma (DIPG) or other brainstem gliomas. The goal is to understand the molecular changes in these tumors by studying RNA and proteins in tumor tissue, normal brain tissue, and spinal fluid. Researchers hope to identify specific markers that can lead to new and more effective treatments. This is an observational study, meaning there are no specific interventions or treatments being tested. The study aims to enroll 100 participants, but its current status is unclear.
- Study design
- This is an observational study designed to collect samples from 100 participants. It is not testing any specific interventions.
- What's involved
- Not specified in the trial record.
- Compensation
- Not stated in the trial record.
- Follow-up
- The primary endpoints, such as analyzing gene expression and protein profiles, will be measured at 5 years.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Molecular Analysis of Samples From Patients With Diffuse Intrinsic Pontine Glioma and Brainstem Glioma
At a glance
Conditions
NCT01106794
Where you'd take part
This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.
Children's National Medical Center
Washington D.C., District of Columbiano site contact published
Recruiting
Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.
Study leadership
- Javad Nazarian, PhD · PRINCIPAL_INVESTIGATOR · Children's National Research Institute
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
Want this trial checked against your situation?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Inclusion
Exclusion
What this trial measures
- Genome-wide expression patterns of RNA in tumor samples, normal brainstem tissue and cerebrospinal fluid using Affymetrix gene expression profiling5 years
Collected tumor and normal samples will potentially be used for RNA genome-wide expression pattern profiling.
- Validation of results of the genome-wide analysis5 years
The molecular analysis done on collected samples will be validated through whole genome sequencing.
- Proteomic profiling of tumor, normal brainstem tissue and cerebrospinal fluid5 years
To obtain full characterization of collected samples, proteomic profiling will be done on tumor and normal samples collected.
- Protein expression patterns as assessed by immunohistochemistry and western blot compared to normal brainstem tissue5 years
Collected tumor and normal samples will have the immunochemistry and western blot compared to assess protein expression variation.
- Genome-wide analysis of tumor samples and normal brainstem tissue5 years
To obtain full characterization of collected samples, whole genome sequencing will be done on tumor and normal samples collected.
- In vitro and in vivo molecular analysis of collected samples5 years
Collected samples will potentially be used for in vitro analysis and generation of animal models of this tumor.